Evidence map›Paper›PMID 29733543›Full record

ArticleCancer medicine2018

Disparities in breast cancer: a multi-institutional comparative analysis focusing on American Hispanics.

Zeina Nahleh, Salman Otoukesh, Hamid Reza Mirshahidi, Anthony Loc Nguyen, Gayathri Nagaraj, Gehan Botrus, Nabeel Badri, Nabih Diab, Andres Alvarado, Luis A Sanchez and 1 more

Open access · goldAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Racial and regional disparities in deaths in breast cancer.Medical oncology (Northwood, London, England) · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zeina NahlehDepartment of Hematology-Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, Florida.
Salman OtoukeshDivision of Hematology-Oncology, Department of Internal Medicine, Loma Linda University Health, Loma Linda, California.ORCID 0000-0002-7871-720X
Hamid Reza MirshahidiDivision of Hematology-Oncology, Department of Internal Medicine, Loma Linda University Health, Loma Linda, California.
Anthony Loc NguyenDepartment of Internal Medicine, Loma Linda University, Loma Linda, California.
Gayathri NagarajDivision of Hematology-Oncology, Department of Internal Medicine, Loma Linda University Health, Loma Linda, California.
Gehan BotrusDepartment of Internal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, Texas.
Nabeel BadriDepartment of Internal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, Texas.
Nabih DiabDepartment of Internal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, Texas.
Andres AlvaradoDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, EL Paso, Texas.
Luis A SanchezDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, EL Paso, Texas.
Alok K DwivediDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, EL Paso, Texas.
Texas Tech University · USLoma Linda University · USCleveland Clinic Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is the leading cause of cancer death in Hispanic/Latino women nationwide. Hispanic women are more likely to be presented with advanced disease and adverse prognosis subtypes. The aim of this study is to describe the clinico- pathological characteristics and disparities in breast cancer in this group at two tertiary care University-based medical centers. After IRB approval, Cancer registry was used to analyze the variables of 3441 patients with breast cancer diagnosed and treated consecutively at two large tertiary University based medical and cancer center database centers in El Paso, TX and Loma Linda, CA between 2005 and 2015. Association between race/ethnicity and cancer type, stage, hormone receptor status and treatment option were investigated. Overall 45.5% of the patients were Hispanic (n: 1566) and those were more likely to be diagnosed at a younger age (57 years) similar to African Americans, more likely to have invasive ductal carcinoma type (82.7%) & triple negative disease (17.1%, 95%CI: 15% to 19%). 58.8% of Hispanics (95%CI: 56% to 61%) have hormone receptor (HR)+ & HER2- as opposed to 71% in non-Hispanic White people. In addition, Hispanic individuals presented with advanced stages of BC (25.3%, 95% CI: 23% to 28%) similar to African American (25.4%), and had a lower proportion of lumpectomy (50%) similar to African American (50%). When compared to African American patients, Hispanic patients had a higher prevalence of triple negative BC (17.11% in Hispanics Versus 13.86% in African American).

conclusionHispanics had significantly higher relative risk of advanced stages at presentation (Relative Risk Ratio (RRR) = 2.05, P < 0.001), triple negative tumors (RRR = 2.64, P < 0.0001), HER2 + /HR - disease (RRR = 1.77, P < 0.0001), and less HR+ /HER2- BC (RRR = 0.69, P < 0.0001). Hispanics and African Americans are diagnosed with breast cancer at a younger age, have a higher prevalence of Triple negative breast cancer, and are diagnosed at more advanced stages of disease. Increasing awareness and targeting minority populations for health promotion interventions, screening and early detection continue to be of paramount importance to reduce the burden of health disparities.

Indexed as

Healthcare DisparitiesHispanic or LatinoAgedBiomarkers, TumorBlack or African AmericanBreast NeoplasmsDisease ManagementEthnicityFemaleHumansMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorAfrican AmericanBreast CancerDisparitiesEthnic differencesHispanicHormone ReceptorTriple Negative

Identifiers

PMID29733543
PMCPMC6010853
OpenAlexW2799804613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.